AU2002338807A1 - Use of c-kit inhibitors for the treatment of myeloma - Google Patents

Use of c-kit inhibitors for the treatment of myeloma

Info

Publication number
AU2002338807A1
AU2002338807A1 AU2002338807A AU2002338807A AU2002338807A1 AU 2002338807 A1 AU2002338807 A1 AU 2002338807A1 AU 2002338807 A AU2002338807 A AU 2002338807A AU 2002338807 A AU2002338807 A AU 2002338807A AU 2002338807 A1 AU2002338807 A1 AU 2002338807A1
Authority
AU
Australia
Prior art keywords
myeloma
treatment
kit inhibitors
inhibitors
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002338807A
Other languages
English (en)
Inventor
Kenneth C. Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002338807A1 publication Critical patent/AU2002338807A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002338807A 2001-09-27 2002-09-26 Use of c-kit inhibitors for the treatment of myeloma Abandoned AU2002338807A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32549101P 2001-09-27 2001-09-27
US60/325,491 2001-09-27
PCT/EP2002/010827 WO2003028711A2 (en) 2001-09-27 2002-09-26 Use of c-kit inhibitors for the treatment of myeloma

Publications (1)

Publication Number Publication Date
AU2002338807A1 true AU2002338807A1 (en) 2003-04-14

Family

ID=23268098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002338807A Abandoned AU2002338807A1 (en) 2001-09-27 2002-09-26 Use of c-kit inhibitors for the treatment of myeloma

Country Status (5)

Country Link
US (2) US20040266779A1 (enExample)
EP (1) EP1432422A2 (enExample)
JP (1) JP4130179B2 (enExample)
AU (1) AU2002338807A1 (enExample)
WO (1) WO2003028711A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032872A1 (fr) 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
WO2004058234A2 (en) * 2002-12-27 2004-07-15 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
WO2007052849A1 (ja) 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
PL3255061T3 (pl) 2006-11-03 2021-12-06 The Board Of Trustees Of The Leland Stanford Junior University Selektywna deplecja immunologiczna niszy endogennych komórek macierzystych do wszczepienia
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
IL302218B2 (en) 2014-08-28 2024-10-01 Eisai R&D Man Co Ltd Methods for manufacturing high-purity lenvatinib and its derivatives
JP6792546B2 (ja) 2015-02-25 2020-11-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
RU2750539C2 (ru) 2017-02-08 2021-06-29 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция для лечения опухоли
AU2018269996A1 (en) 2017-05-16 2019-11-21 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US11786557B2 (en) 2017-10-02 2023-10-17 Fred Hutchinson Cancer Center Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
EP1165085B1 (en) * 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
WO2002089772A1 (en) * 2001-05-09 2002-11-14 Inex Pharmaceuticals Corporation Anti-angiogenic therapy using liposome-encapsulated chemotherapeutic agents

Also Published As

Publication number Publication date
EP1432422A2 (en) 2004-06-30
JP2005504111A (ja) 2005-02-10
WO2003028711A2 (en) 2003-04-10
JP4130179B2 (ja) 2008-08-06
WO2003028711A3 (en) 2003-08-28
US20090170862A1 (en) 2009-07-02
US20040266779A1 (en) 2004-12-30

Similar Documents

Publication Publication Date Title
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
AU2002256418A1 (en) Inhibitors of bace
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU2001285747A1 (en) Method for the treatment of tobacco
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
AU2003260778A1 (en) Treatment of pipes
AU2002303145A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
HUP0500285A3 (en) Methods for the purification of levofloxacin
AU2003233820A1 (en) Method for the treatment of starch
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2002305868A1 (en) Inhibitors of reggamma
AU2003264822A1 (en) Epothilone derivatives for the treatment of multiple myeloma
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
PL371270A1 (en) Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine
AU2003262140A1 (en) Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
AU2002343085A1 (en) Tnf-alpha inhibitors for the treatment of hepatic diseases
AU2002249232A1 (en) Use of $g(g)-gt inhibitors for the treatment of degenerative diseases
AU2002334310A1 (en) 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders
AU2002248689A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2002318129A1 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase